NLM Digital Collections

Search

Start Over Subjects Insurance, Pharmaceutical Services -- economics ✖Remove constraint Subjects: Insurance, Pharmaceutical Services -- economics

3. Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
Subject(s):
Abuse-Deterrent Formulations -- economics
Abuse-Deterrent Formulations -- statistics & numerical data
Analgesics, Opioid -- economics
Analgesics, Opioid -- therapeutic use
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- prevention & control
Prescription Drug Diversion -- statistics & numerical data
Comparative Effectiveness Research
Cost-Benefit Analysis
Delayed-Action Preparations -- economics
Delayed-Action Preparations -- therapeutic use
Drug Compounding -- economics
Drug Overdose -- mortality
Insurance Coverage -- economics
Insurance, Pharmaceutical Services -- economics
Opioid-Related Disorders -- epidemiology
Humans
United States

5. California employer health benefits: workers shoulder more costs

Author(s):
Whitmore, Heidi, author
Gabel, Jon, author
Publication:
Oakland, CA : California Health Care Foundation, June 2018
Subject(s):
Health Benefit Plans, Employee -- economics
Health Benefit Plans, Employee -- statistics & numerical data
Health Benefit Plans, Employee -- trends
Ambulatory Care Facilities
Deductibles and Coinsurance -- statistics & numerical data
Forecasting
Health Maintenance Organizations -- statistics & numerical data
Insurance -- statistics & numerical data
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- statistics & numerical data
Insurance, Pharmaceutical Services -- trends
Managed Care Programs -- economics
Managed Care Programs -- statistics & numerical data
Managed Care Programs -- trends
Small Business -- statistics & numerical data
Telemedicine
State Government
Humans
California
United States

6. Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, D.C. : U.S. Government Accountability Office, July 18, 2017
Subject(s):
Government Regulation
Insurance, Pharmaceutical Services -- economics
Medicaid -- economics
Contract Services
Economics, Pharmaceutical
Forecasting
Government Programs -- statistics & numerical data
Insurance, Health, Reimbursement
Pharmacies -- statistics & numerical data
Pharmacies -- trends
Humans
United States
United States. Health Resources and Services Administration.

7. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system